Launch of Favipiravir to treat Covid patients: Announced by Glenmark

Published by admin on

Launch of Favipiravir to treat Covid patients: Announced by Glenmark

FabiFlu® the first oral Favipiravir-approved medication in India for the treatment of Covid-19, announced by Glenmark it has received manufacturing and marketing approval from India’s drug regulator, making officials said at a press conference organised online.

Glenmark Pharmaceuticals on Saturday reported the dispatch of antiviral medication Favipiravir (brand name FabiFlu®) for the treatment of mellow to direct Covid-19 patients.

Glenmark has gotten assembling and promoting endorsement from India’s medication controller, making FabiFlu® the first oral Favipiravir-affirmed drug in Quite a while for the treatment of Covid-19, authorities said at a question and answer session composed on the web

The antiviral offers wide range RNA infection inclusion with clinical improvement noted across age bunches 20 to >90 years. Favipiravir can be utilized in Covid-19 patients with co-horrible conditions, for example, diabetes and coronary illness with gentle to direct Covid-19 side effects. It offers quick decrease in viral burden inside four days and gives quicker indicative and radiological improvement.

Of most significance, Favipiravir has shown clinical improvement of up to 88 percent in gentle to direct Covid-19 cases, an official explanation said.

Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd, said FabiFlu® has shown a urging reaction in gentle to direct Covid-19 patients during clinical preliminaries.


https://indianexpress.com/article/india/glenmark-announces-launch-of-favipiravir-to-treat-covid-patients-6468678/


0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *